Influence of Vancomycin Infusion Methods on Endothelial Cell

Peripheral intravenous therapy is frequently used in routine hospital practice and, due to various factors, its most common side effect is phlebitis. The infusion of vancomycin is particularly associated with phlebitis despite its widespread use. French guide-lines recommend central intravenous infusion for high concentrations of vancomycin, but peripheral intravenous therapy is often preferred in intensive care units. Methods of vancomycin infusion are either intermittent infusion or continuous infusion. A comparison of these methods under in vitro conditions simulating clinical use could result in better infusion efficacy. Human umbilical vein endothelial cells (HUVECs) were therefore challenged with clinical doses of vancomycin over a 24- to 72-h period using these infusionmethods. Cell death was measured with the alamarBlue test. Concentration-dependent and time-dependent vancomycin toxicity on HUVECs was noted with a 50 % lethal dose at 5 mg/ml after 24 h, reaching 2.5 mg/ml after 72 h of infu-sion, simulating long-term infusion. This toxicity does not seem to be induced by acidic pH. In comparing infusionmethods, we observed that continuous infusion induced greater cell toxicity than intermittent infusion at doses higher than 1 g/day. The in-creasing use of vancomycin means that new guidelines are required to avoid phlebitis. If peripheral intravenous therapy is used to reduce infusion time, along with intermittent infusion, vein irritation and localized phlebitis may be reduced. Further studies have to be carried out to explore the causes of vancomycin endothelial toxicity. Intravenous (i.v.) therapy is one of the most common routinemedical practices performed in hospitals, due to the increasin